CERVICAL SQUAMOUS CELL CARCINOMA
Clinical trials for CERVICAL SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new CERVICAL SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for CERVICAL SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug ALE.P02 targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new drug called ALE.P02 in people with advanced squamous cell cancers of the lung, head and neck, cervix, or esophagus that have spread or cannot be removed. The goal is to find the safest and most effective dose and see if it can shrink tumors. About 170 adult…
Matched conditions: CERVICAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug EVOLVE104 takes on tough cancers in early human trial
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell carcinoma (lung, esophagus, skin, and others). The study aims to find a safe dose and see if the drug can shrink tumors. It is for pati…
Matched conditions: CERVICAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: EvolveImmune United, Inc • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug cocktail targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new antibody called HMBD-001 combined with two existing cancer drugs (cetuximab and docetaxel) in people with advanced squamous cell cancers of the lung, head and neck, esophagus, cervix, or skin. The goal is to see if the combination is safe and can shrink tum…
Matched conditions: CERVICAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Hummingbird Bioscience • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New Antibody-Drug conjugate takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called ALE.P03 in adults with advanced or metastatic solid tumors that have a specific protein (Claudin-1) on their surface. The drug is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The trial has two phases: …
Matched conditions: CERVICAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New radioactive drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new radioactive drug, [177Lu]Lu-AKIR001, in 15 adults with advanced solid tumors (like thyroid, head and neck, cervical, vulvar, or lung cancer) that have stopped responding to standard treatments. The main goal is to check the drug's safety and sid…
Matched conditions: CERVICAL SQUAMOUS CELL CARCINOMA
Phase: EARLY_PHASE1 • Sponsor: Karolinska University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Virus therapy takes on cervical and endometrial cancer
Disease control Recruiting nowThis study tests a modified virus (KD01) that targets and kills cancer cells, given alone or with an immunotherapy drug (AK104). It includes 97 women with cervical or endometrial cancer, some of whom have not responded to standard treatments. The goal is to see if the virus is sa…
Matched conditions: CERVICAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug combo aims to stop cervical cancer recurrence in high-risk patients
Disease control Recruiting nowThis study tests whether adding the drug serplulimab to standard chemoradiotherapy after surgery can help prevent cervical cancer from returning in patients with multiple risk factors. About 134 women aged 18-65 with PD-L1 positive cervical cancer will be randomly assigned to rec…
Matched conditions: CERVICAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New smart drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called DAY301 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a powerful toxin directly to cancer cells while sparing healthy ones. The study aims to find the safest dose …
Matched conditions: CERVICAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC